FS-207 / Foresight Therapeutics - LARVOL DELTA

A single-arm, open-label Phase Ia/Ib clinical trial to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of FS-207 tablets in patients with advanced solid tumors with high microsatellite instability (MSI-H) (ChiCTR) - P1 | N=156 | Not yet recruiting | Sponsor: Beijing Cancer Hospital; Fushi Biotechnology (Hefei) Co., Ltd

MSI-H • New P1 trial • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor • MSI

A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) (clinicaltrials.gov) - P1 | N=156 | Not yet recruiting | Sponsor: Foresight Therapeutics (Hefei) Co., Ltd.

MSI-H • New P1 trial • Microsatellite Instability • Oncology • Solid Tumor • MSI

FS-207: A potential best-in-class WRN helicase inhibitor for treating MSI-H cancers (AACR 2026) - "Our findings position FS-207 as a promising, potentially best-in-class WRN helicase inhibitor for the treatment of MSI-H cancers, owing to its superior efficacy, durability, and selectivity. FS-207 is poised to enter clinical trials in 2026."

MSI-H • Microsatellite Instability • Oncology • MSI • WRN